We are live on ! Find out more
FGP

Foyston, Gordon, & Payne Portfolio holdings

AUM $468M
1-Year Est. Return 6.67%
This Fund
S&P 500
This Quarter Est. Return
+1.05%
1 Year Est. Return
+6.67%
3 Year Est. Return
+57.25%
5 Year Est. Return
+83.16%
10 Year Est. Return
+253.32%
AUM
$576M
AUM Growth
+$112M
Cap. Flow
+$110M
Cap. Flow %
19.04%
Top 10 Hldgs %
51.94%
Holding
67
New
3
Increased
30
Reduced
21
Closed
4

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$27.5M
2
UNH icon
UnitedHealth
UNH
+$23.9M
3
MDT icon
Medtronic
MDT
+$13.4M
4
NVS icon
Novartis
NVS
+$6.8M
5
MSFT icon
Microsoft
MSFT
+$6.22M

Top Sells

Rank Stock Value
1
COL
Rockwell Collins
COL
+$12.1M
2
BG icon
Bunge Global
BG
+$3.79M
3
PFE icon
Pfizer
PFE
+$2.92M
4
BHI
Baker Hughes
BHI
+$2.64M
5
JCI icon
Johnson Controls International
JCI
+$2.42M

Sector Composition

Rank Sector Weight
1 Healthcare 36.3%
2 Technology 18.5%
3 Industrials 13.86%
4 Financials 12.79%
5 Consumer Staples 7.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
1
Johnson & Johnson
JNJ
$646B
$53.4M 9.27%
410,775
+207,088
+102% +$27.5M
MDT icon
2
Medtronic
MDT
$117B
$43.8M 7.61%
563,720
+160,884
+40% +$13.4M
MSFT icon
3
Microsoft
MSFT
$3.81T
$29.6M 5.14%
397,213
+85,176
+27% +$6.22M
UNH icon
4
UnitedHealth
UNH
$353B
$28.7M 4.99%
146,712
+123,886
+543% +$23.9M
AON icon
5
Aon
AON
$75.4B
$27.8M 4.83%
190,602
+40,364
+27% +$5.63M
WBA
6
DELISTED
Walgreens Boots Alliance
WBA
$27.7M 4.81%
358,794
+37,006
+12% +$2.97M
ORCL icon
7
Oracle
ORCL
$435B
$26M 4.51%
537,166
+99,588
+23% +$4.96M
WFC icon
8
Wells Fargo
WFC
$262B
$21.8M 3.79%
396,178
+35,453
+10% +$1.88M
AXP icon
9
American Express
AXP
$225B
$20.8M 3.6%
229,473
+64,199
+39% +$5.52M
RTX icon
10
RTX Corp
RTX
$285B
$19.5M 3.39%
267,569
+70,714
+36% +$5.23M
UNP icon
11
Union Pacific
UNP
$183B
$18.9M 3.28%
162,787
+37,297
+30% +$4M
MSI icon
12
Motorola Solutions
MSI
$80.4B
$16.4M 2.84%
192,974
+32,770
+20% +$2.87M
PEP icon
13
PepsiCo
PEP
$193B
$15.7M 2.72%
140,697
-309
-0.2% -$35.7K
NVS icon
14
Novartis
NVS
$292B
$14.4M 2.5%
187,179
+90,054
+93% +$6.8M
CSCO icon
15
Cisco
CSCO
$433B
$13.9M 2.42%
414,730
+93,960
+29% +$2.99M
BAX icon
16
Baxter International
BAX
$13.5B
$12.5M 2.17%
198,804
+37,137
+23% +$2.29M
GNTX icon
17
Gentex
GNTX
$4.78B
$12M 2.08%
605,501
+231,045
+62% +$4.2M
CHKP icon
18
Check Point Software Technologies
CHKP
$14.1B
$11.5M 1.99%
100,540
+34,187
+52% +$3.76M
TFCFA
19
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
$11.3M 1.97%
429,246
+126,533
+42% +$3.49M
PFE icon
20
Pfizer
PFE
$159B
$11.1M 1.93%
327,796
-90,952
-22% -$2.92M
JCI icon
21
Johnson Controls International
JCI
$84.6B
$9.9M 1.72%
245,724
-59,908
-20% -$2.42M
GWW icon
22
W.W. Grainger
GWW
$61.5B
$9.14M 1.59%
50,864
+14,054
+38% +$2.37M
NVO
23
Novo Nordisk
NVO
$202B
$8.26M 1.43%
342,944
+113,882
+50% +$2.57M
CHRW icon
24
C.H. Robinson
CHRW
$17.6B
$6.56M 1.14%
86,211
+1,972
+2% +$137K
LHX icon
25
L3Harris
LHX
$48.9B
$5.69M 0.99%
43,231
+13,169
+44% +$1.58M
1
2 3

Similar funds

GC
Guidance Capital Lousville, Kentucky $468M AUM 26.09% 1-Year Est. Return
SCP
Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return
THC
Truffle Hound Capital Bethesda, Maryland $468M AUM 42.57% 1-Year Est. Return
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $468M AUM 19.67% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
QFA
Quattro Financial Advisors The Woodlands, Texas $468M AUM 13.49% 1-Year Est. Return
TOCUITCONY
Trustees of Columbia University in the City of New York New York $468M AUM 20.53% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return

Foyston, Gordon, & Payne's Q3 2017 Portfolio in Review

As of Q3 2017, Foyston, Gordon, & Payne held 67 positions worth $576M, up 24% from $464M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Foyston, Gordon, & Payne deployed $110M of net new capital in Q3 2017, opening 3 new positions and adding to 30 existing holdings. Its largest new stake was Baker Hughes: 140,613 shares worth $5.15M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 29% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Pfizer, an estimated $2.92M trimmed.

  • Foyston, Gordon, & Payne's largest Q3 2017 buy was Baker Hughes: 140,613 shares worth $5.15M.
  • Foyston, Gordon, & Payne added most to Johnson & Johnson in Q3 2017, an estimated $27.5M increase.
  • Foyston, Gordon, & Payne's biggest Q3 2017 reduction was Pfizer, cutting an estimated $2.92M.
  • Foyston, Gordon, & Payne fully exited Rockwell Collins in Q3 2017, selling an estimated $12.1M.
  • Foyston, Gordon, & Payne's ten largest holdings make up 52% of its $576M portfolio in Q3 2017.
  • Foyston, Gordon, & Payne opened 3 new positions and closed 4 in Q3 2017.
  • Foyston, Gordon, & Payne's portfolio value rose 24% quarter-over-quarter to $576M.

Based on Foyston, Gordon, & Payne's 13F filing for Q3 2017, filed 14 Nov 2017.